Advanced hepatocellular carcinoma can be treated with targeted drugs such as sorafenib, lenvatinib and regorafenib. Advanced hepatocellular carcinoma often has multiple lymph node metastasis or distant metastasis, at this time, it is no longer suitable for surgical treatment, and radiotherapy, targeted drugs or immunotherapy are often used to slow down the progress of the disease. The more commonly used first-line targeted drugs are sorafenib and lenvatinib, which belong to anti-angiogenic drugs that can inhibit angiogenesis and cut off the blood and nutrient supply of the tumor, so as to achieve the effect of shrinking the tumor and controlling the condition. If patients are resistant to first-line targeted drugs or the effect is not good, they can also consider second-line targeted drugs such as regorafenib and apatinib. During the period of medication, there may be gastrointestinal bleeding, regurgitation and other adverse reactions, so it is necessary to follow the doctor’s instructions to use the medication reasonably, and should not arbitrarily cut down or stop taking the medication.